# Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

Study · id `cardio:ct-nct02730455` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02730455](<https://clinicaltrials.gov/study/NCT02730455>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02730455

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 277 participants.

## Technical summary

Registry record NCT02730455. Randomized; quadruple masking; primary purpose treatment. Start 2016-07-18 (actual); primary completion 2017-11-20 (actual). Results posted on 2019-01-08.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 277 participants (enrolled count; ClinicalTrials.gov record NCT02730455, source copy `cardio:ctgov-nct02730455-2019-01-08`, retrieved 2026-10-26)
- Started: 2016-07-18 (actual) (ClinicalTrials.gov record NCT02730455, source copy `cardio:ctgov-nct02730455-2019-01-08`, retrieved 2026-10-26)
- Primary completion: 2017-11-20 (actual) (ClinicalTrials.gov record NCT02730455, source copy `cardio:ctgov-nct02730455-2019-01-08`, retrieved 2026-10-26)
- Completion: 2017-11-20 (actual) (ClinicalTrials.gov record NCT02730455, source copy `cardio:ctgov-nct02730455-2019-01-08`, retrieved 2026-10-26)
- Results first posted: 2019-01-08 (ClinicalTrials.gov record NCT02730455, source copy `cardio:ctgov-nct02730455-2019-01-08`, retrieved 2026-10-26)
- Countries: United States; Germany; Spain; United Kingdom (ClinicalTrials.gov record NCT02730455, source copy `cardio:ctgov-nct02730455-2019-01-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02730455-2019-01-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
- Acronym: ACTION2
- Condition: Acute Ischemic Stroke
- Intervention (Drug): natalizumab
- Intervention (Drug): Placebo
- Lead sponsor: Biogen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Biogen (`cardio:org-biogen`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial (`cardio:pubmed-32591475`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cb4a277d1fa66f081794d8d33e65dabf089d4c0c2c3abc16e0bcab2f11c06071
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
